Pfizer scores again in HER2-positive breast cancer, this time with Seagen's Tukysa

14th October 2025 Uncategorised 0

The positive readout could move Tukysa, which has been used for second-line, HER2-positive breast cancer, into the earlier, first-line maintenance setting.

More: Pfizer scores again in HER2-positive breast cancer, this time with Seagen's Tukysa
Source: fierce